## White House Drafts Drug Pricing Bill, Seeks Pharma Support in Private Meetings
The White House is privately circulating draft legislative text for its drug pricing policy to more than a dozen major pharmaceutical companies, signaling a critical push to secure industry backing. This move, confirmed by people familiar with the meetings, represents a concrete step beyond public rhetoric, placing detailed policy proposals directly into the hands of the companies it aims to regulate. The administration's strategy hinges on converting voluntary agreements into binding law, with the draft text reportedly mirroring the outlines of those prior deals.

The core of the draft legislation includes a specific policy that would allow drugs purchased with cash to count toward a patient’s deductible, a provision directly impacting consumer costs and insurer calculations. This legislative push is a central component of the Trump administration's broader health reform agenda, which has gained heightened political urgency in an election year. The president's personal focus on his affordability platform has elevated the stakes, turning these private negotiations into a key battleground for a significant policy win.

The closed-door nature of these discussions underscores the delicate balance the White House must strike: applying pressure for reform while attempting to win over an industry historically resistant to government price controls. The outcome of these meetings could determine the viability of the bill, shaping not only the legislative landscape but also the political narrative around healthcare affordability ahead of the election. The administration's ability to align pharmaceutical company support with its policy ambitions now faces a direct test.
---
- **Source**: STAT News
- **Sector**: The Network
- **Tags**: pharmaceuticals, drug pricing, health policy, legislation, lobbying
- **Credibility**: unverified
- **Published**: 2026-03-27 18:27:08
- **ID**: 38162
- **URL**: https://whisperx.ai/en/intel/38162